New treatment strategies for malignant gliomas

Oncologist

Volumn 4, Issue 3, 1999, Pages 209-224

  Avgeropoulos, Nicholas G ^a   Batchelor, Tracy T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Antisense; Chemotherapy; Clinical trials; Cytokine; Gene therapy; Glioma; Immunotherapy

Indexed keywords

9 AMINOCAMPTOTHECIN; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTICONVULSIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CARMUSTINE; CYTOKINE; CYTOTOXIC AGENT; INTERLEUKIN 2; IRINOTECAN; ISIS 3521; LOBRADIMIL; MANNITOL; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PLACEBO; POLYMER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; STAUROSPORINE; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; THYMIDINE KINASE; TOPOTECAN;

ALOPECIA; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; FATIGUE; GASTROINTESTINAL TOXICITY; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RETROVIRUS; SENSORY NEUROPATHY; T LYMPHOCYTE;

EID: 0033023072     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-3-209     Document Type: Article

References (126)

1. Salcman M, Scholtz H, Kaplan RS et al. Long-term survival in patients with malignant astrocytoma. Neurosurgery 1994;34:213-219.
2. Fine HA, Dear KB, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-2597.
3. Salcman M. Survival in glioblastoma: historical perspective. Neurosurgery 1980;7:435-439.
4. Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1415 patients. Anticancer Res 1998;18:1303-1312.
5. Perry JR, DeAngelis LM, Schold SC Jr et al. Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 1997;49:912-917.
6. Kaplan RS. Complexities, pitfalls, and strategies for evaluating brain tumor therapies. Curr Opin Oncol 1998;10:175-178.
7. Fetell MR, Grossman SA, Fisher JD et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997;15:3121-3128.
8. Hochberg F, Grossman SA, Mikkelsen T et al. Efficacy of 9-aminocamptothecin (9-AC) in adults with newly diagnosed glioblastoma multiforme (GBM) and recurrent high grade astrocytomas (HGA). Proc Am Soc Clin Oncol 1998;17:388.
9. Macdonald DR, Cascino TL, Schold SC et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
10. Burger PC, Vogel FS, Green SB et al. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985;56:1106-1111.
11. Coons SW, Johnson PC, Scheithauer BW et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-1393.
12. Daumas-Duport C, Scheithauer B, O'Fallon J et al. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-2165.
13. Schwartz CE, Cole BF, Gelber RD. Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method. Arch Neurol 1995;52:754-762.
14. Weitzner M, Meyers C, Gelke C et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995;75:1151-1161.
15. Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 1997;34:263-278.
16. Hutchinson TA, Boyd NF, Feinstein AR. Scientific problems in clinical scales, as demonstrated in the Karnofsky Index of Performance Status. J Chronic Dis 1979;32:661-666.
17. Wedge SR, Newlands ES. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 1996;73:1049-1052.
18. Newlands ES, Stevens MF, Wedge SR et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
19. Newlands ES, Blackledge GRP, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-291.
20. Brock CS, Newlands ES, Wedge SR et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-4367.
21. Newlands ES, O'Reilly SM, Glaser MG et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996;32A:2236-2241.
22. Bower M, Newlands ES, Bleehen NM et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997;40:484-488.
23. Levin VA, Yung A, Prados M et al. Temodal (temozolomide) at first relapse in anaplastic astrocytoma patients. J Neurooncol 1997;35(suppl 1):185a.
24. Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-3857.
25. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-855.
26. Tanizawa A, Fujimori A, Fujimori Y et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-842.
27. Nakatsu S, Kondo S, Kondo Y et al. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 1997;39:417-423.
28. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245-259.
29. Gupta E, Wang X, Ramirez J et al. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997;39:440-444.
30. Hare CB, Elion GB, Houghton PJ et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1997;39:187-191.
31. Colvin OM, Cokgor I, Ashley DM et al. Irinotecan treatment of adults with recurrent or progressive malignant glioma. Proc Am Soc Clin Oncol 1998;17:1493a.
32. Sung C, Blaney S, Cole D et al. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 1994;54:5118-5122.
33. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-3061.
34. Dennis MJ, Beijnen JH, Grochow LB et al. An overview of the clinical pharmacology of topotecan. Semin Oncol 1997;24(suppl 5):S5-12-S5-18.
35. Creemers GJ, Gerrits CJ, Eckardt JR et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997;15:1087-1093.
36. Managold C, Pawal JV, Scheithauer W et al. Response of SCLC brain metastases to topotecan (SK&F 104864) therapy. Ann Oncol 1996;7(suppl 5):106.
37. Macdonald D, Cairncross G, Stewart D et al. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 1996;7:205-207.
38. Blaney SM, Phillips PC, Packer RJ et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996;78:527-531.
39. Eisenhauer EA, Wainman N, Boos G et al. Phase II trials of topotecan in patients with malignant glioma and soft tissue sarcoma. Proc Am Soc Clin Oncol 1994;13:A488.
40. Kyritsis A, Newlands ES, Brock CS et al. Phase II trial of topotecan as a continuous intravenous infusion in patients with high grade gliomas. Proc Am Soc Clin Oncol 1997;16:A1404.
41. Dropcho E, Rosenfeld S, Morawetz R et al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. J Clin Oncol 1992;10:452-458.
42. Gruber ML, Glass J, Choudhri H et al. Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. Am J Clin Oncol 1998;21:338-340.
43. Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 1998;25(suppl 5):23-31.
44. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350:681-686.
45. Extra JM, Marty M, Brienza S et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25(suppl 5):13-22.
46. Brienza S, Vignoud J, Itzhaki M et al. Oxaliplatin (I-OHP): global safety in 682 patients. Proc Am Soc Clin Oncol 1995;14:A513.
47. Misset JL, Kidani J, Gastiaburu C et al. Oxaliplatinum (I-OHP): experimental and clinical studies. In: Howell SB, ed. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. New York: Plenum Press, 1991:369-375.
48. Soulie P, Raymond E, Brienza S et al. Oxaliplatin: the first DACH platinum in clinical practice. Bull Cancer 1997;84:665-673.
49. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications of cellular regulation. Nature 1988;334:661-665.
50. Couldwell WT, Uhm JH, Antel JP et al. Enhanced protein kinase C activity correlates with the growth of malignant glioma in vitro. Neurosurgery 1991;29:880-887.
51. Baltuch GH, Yong VW. Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. Brain Res 1996;710:143-149.
52. Agrawal S, Temsamani J, Galbraith W et al. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995;28:7-16.
53. Gerwitz AM, Stein CA, Glazer PM. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci USA 1996;93:3161-3163.
54. Dean NM, McKay R, Condon TP et al. Inhibition of protein kinase C-ax expression in human A549 cells by antisense oligonucleotides inhibits induction of intracellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 1994;269:16416-16424.
55. Smith CUM. Elements of Molecular Neurobiology. New York: John Wiley and Sons, 1996:60.
56. Pollack IF, Randall MS, Kristofik MP et al. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 1990;50:7134-7138.
57. O'Brian CA, Liskamp RM, Solomon DH et al. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985;45:2452-2465.
58. Butta A, MacLennan K, Flander KC et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52:4261-4264.
59. Vertosik FT, Selker RG, Pollack IF et al. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery 1992;30:897-903.
60. Couldwell WT, Weiss MH, DeGiorgio CM et al. Clinical and radiographic response in a minority of patients with recurrent malfgnant gliomas treated with high-dose tamoxifen. Neurosurgery 1993;32:485-489.
61. Vertosick FT Jr, Selker RG, Arena V. A dose-escalation study of tamoxifen therapy in patients with recurrent glioblastoma multiforme. J Neurosurg 1994;80:385A.
62. Freeman A, Hetherington M, Egelhoff J et al. Preliminary results: diffuse intrinsic brain stem gliomas of childhood respond to tamoxifen. Proc Am Assoc Cancer Res 1994;35:470.
63. Couldwell WT, Hinton DR, Surnock AA et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996;2:619-622.
64. Pollack IF, DaRosso RC, Robertson PL et al. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 1997;3:1109-1115.
65. Preul MC, Caramanos Z, Shenouda G et al. In vivo biochemical effects of tamoxifen on recurrent malignant astrocytomas: characteristics of response and failure. J Neurosurg 1996;84:352A-353A.
66. Lien EA, Wester K, Lonning PE et al. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 1991;63:641-645.
67. Baltuch GH, Couldwell WT, Villemure JG et al. Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 1993;33:495-501.
68. Boral AL, Dessain S, Chabner BA. Clinical evaluation of biologically targeted drugs: obstacles and opportunities. Cancer Chemother Pharmacol 1998;42(suppl):S3-S21.
69. Kang MS, Stemerick DM, Zwolshen JH et al. Farnesyl-derived inhibitors of ras farnesyl transferase. Biochem Biophys Res Commun 1995;217:245-249.
70. Bredel M, Pollack IF, Freund JM et al. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery 1998;43:124-131.
71. Feldkamp MM, Lau N, Guha A. Signal transduction pathways and their relevance in human astrocytomas. J Neurooncol 1997;35:223-248.
72. Moasser MM, Sepp-Lorenzino L, Kohl NE et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998;95:1369-1374.
73. Fetell MR, Housepian EM, Oster MW et al. Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study. Cancer 1990;65:78-83.
74. Yung WK, Prados M, Levin VA et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 1991;9:1945-1949.
75. Buckner JC, Brown LD, Kugler JW et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 1995;82:430-435.
76. Chang SM, Barker FG II, Huhn SL et al. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol 1998;37:169-176.
77. Yung WK, Castellanos AM, Van Tassel P et al. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma. J Neurooncol 1990;9:29-34.
78. Allen J, Packer R, Bleyer A et al. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors. J Clin Oncol 1991;9:783-788.
79. Yung WK, Prados M, Levin VA et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 1991;9:1945-1949.
80. Rajkumar SV, Buckner JC, Schomberg PJ et al. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys 1998;40:297-302.
81. Brandes AA, Scejzi E, Zampieri P et al. Phase II trial with BCNU plus alpha interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol 1997;20:364-367.
82. Kaye AH, Laws ER. Brain Tumors. New York: Churchill Livingstone, 1997:118.
83. Hayes RL, Koslow M, Hiesiger EM et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995;76:840-852.
84. Plautz GE, Barnett GH, Miller DW et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998;89:42-51.
85. Ridet JL, Privat A. Gene therapy in the central nervous system: direct versus indirect gene delivery. J Neurosci Res 1995;42:287-293.
86. Smith GM. Adenovirus-mediated gene transfer to treat neurologic disease. Arch Neurol 1998;55:1061-1064.
87. Ram Z, Culver KW, Oshiro EM et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-1361.
88. Izquierdo M, Martin V, de Felipe P et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 1996;3:491-495.
89. Izquierdo M, Cortes ML, Martin V et al. Gene therapy in brain tumours: implications of the size of glioblastoma on its curability. Acta Neurochir Suppl (Wien) 1997;68:111-117.
90. Mercer WE, Shields MT, Amin M et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 1990;87:6166-6170.
91. Bischoff JR, Kim DH, Williams A et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-376.
92. Hall AR, Dix BR, O'Carroll SJ et al. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998;4:1068-1072.
93. Goodrum F, Ornelles D. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998;72:9479-9490.
94. Linke SP. Cancer. Has the smart bomb been defused? Nature 1998;395:13, 15
95. Lane DP. Killing tumor cells with viruses - a question of specificity. Nat Med 1998;4:1012-1013.
96. Fueyo J, Gomez-Manzano C, Yung WK et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998;4:685-690.
97. Li VW, Folkerth RD, Watanabe H et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 1994;344:82-86.
98. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
99. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
100. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
101. Harris A. Antiangiogenesis for cancer therapy. Lancet 1997;349(suppl II):13-15.
102. Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H et al. Tumor angiogenesis - a new therapeutic target in gliomas. Acta Neurol Scand 1998;97:52-62.
103. Friedberg MH, Glantz MJ, Klempner MS et al. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998;82:923-930.
104. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996;39:235-252.
105. Jekunen AP, Kairemo KJ. Inhibition of malignant angiogenesis. Cancer Treat Rev 1997;23:263-286.
106. Nakagawa T, Kubota T, Kabuto M et al. Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix. J Neurooncol 1996;28:13-24.
107. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol 1995;6:967-974.
108. McCarty MF. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997;49:123-131.
109. Yung WKA. A NCNSC phase II trial of thalidomide, an antiangiogenic agent, in patients with recurrent malignant gliomas. J Neurooncol 1997;35(suppl 56):206a.
110. Sanovich E, Bartus RT, Friden PM et al. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995;705:125-135.
111. Reichman HR, Farrell CL, Del Maestro RF. Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model. J Neurosurg 1986;65:233-237.
112. Neuwelt EA, Barnett PA, Bigner DD et al. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA 1982;79:4420-4423.
113. Riley MG, Kim NN, Watson VE et al. Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: a toxicologic evaluation in swine. J Neurooncol 1998;36:167-178.
114. Sanovich E, Bartus RT, Friden PM et al. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995;705:125-135.
115. Matsukado K, Inamura T, Nakano S et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996;39:125-133; discussion 133-134.
116. Matsukado K, Nakano S, Bartus RT et al. Steroids decrease uptake of carboplatin in rat gliomas - uptake improved by intracarotid infusion of bradykinin analog, RMP-7. Acta Neurochir Suppl (Wien) 1997;70:159-161.
117. Fike JR, Gobbel GT, Mesiwala AH et al. Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain. J Neurooncol 1998;37:199-215.
118. Gregor A, Lind M, Osborn C. RMP-7 and carboplatin in recurrent malignant glioma. J Neurooncol 1997;35(suppl 54):200a.
119. Hochberg FH, Pruit A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-911.
120. Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44-48; discussion 48-49.
121. Fung LK, Ewend MG, Sills A et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58:672-684.
122. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-1012.
123. Walter KA, Cahan MA, Gur A et al. Interstitial Taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 1994;4:2207-2212.
124. Judy KD, Olivi A, Buahin KG et al. Controlled release of a cyclophosphamide derivative with polymers is effective against rat gliomas. J Neurosurg 1995;82:103-108.
125. Olivi A, Ewend MG, Utsuki T et al. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother Pharmacol 1996;39:90-96.
126. Kong Q, Kleinschmidt-Demasters BK, Lillehei KO. Intralesionally implanted cisplatin cures primary brain tumor in rats. J Surg Oncol 1997;64:268-273.